Gilead Sciences has a total of 17232 patents globally, out of which 7456 have been granted. Of these 17232 patents, more than 54% patents are active. United States of America is where Gilead Sciences has filed the maximum number of patents, followed by Japan and Australia. Parallelly, USA seems to be the main focused R&D center and is also the origin country of Gilead Sciences.
Gilead Sciences was founded in 1987 by Michael L. Riordan. Gilead Sciences is a research-based biopharmaceutical company that discovers, develops, and commercializes therapeutics to advance the care of patients suffering from life-threatening diseases. The company primary areas of focus include HIV, AIDS, liver disease, and serious cardiovascular and respiratory conditions. As of February 2022, Gilead Sciences has a market cap of $76.58 Billion.
Do read about some of the most popular patents of Gilead Sciences which have been covered by us in this article and also you can find Gilead Sciences patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Gilead Sciences patent portfolio.
How many patents does the CEO of Gilead Sciences have?
The CEO, Daniel O’Day have 0 patents.
How many patents does Gilead Sciences have?
Gilead Sciences has a total of 17232 patents globally. These patents belong to 1810 unique patent families. Out of 17232 patents, 9465 patents are active.
How many Gilead Sciences patents are Alive/Dead?
Worldwide Patents
How Many Patents did Gilead Sciences File Every Year?
Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.
| Year of Patents Filing or Grant | Gilead Sciences Applications Filed | Gilead Sciences Patents Granted |
| 2011 | 1002 | 300 |
| 2012 | 992 | 391 |
| 2013 | 1112 | 433 |
| 2014 | 1116 | 494 |
| 2015 | 1286 | 653 |
| 2016 | 1062 | 663 |
| 2017 | 1005 | 820 |
| 2018 | 853 | 661 |
| 2019 | 711 | 530 |
| 2020 | 478 | 473 |
| 2021 | 293 | 494 |
| 2022 | 2 | 56 |
Which Gilead Sciences Drug Patents are Expiring in the Next 10 Years?
The patent no. US8822430B2 which is expiring in May, 2030, describes a beneficial amount of a new compound is used to suppress the activity of hepatitis C virus (HCV). This compound has improved properties, such as better inhibition of viral resistance, enhanced oral absorption, increased potency against HCV, or a longer effective duration in the body.
Given below is the list of few drugs patented by Gilead Sciences accompanied by a patent relevant to the drug which will be available for generic drug manufacturing and usage within the next/upcoming 10 years for treatment of various diseases and disorders.
| Drug Name | Patent Number | Patent Title | Patent Expiration |
| Harvoni | US8822430B2 | Antiviral compounds | May, 2030 |
| Vosevi | US9284342B2 | Nucleoside phosphoramidates | Sep, 2030 |
| Epclusa | US8889159B2 | Compositions and methods for treating… | Mar, 2029 |
| Genvoya | US9296769B2 | Tenofovir alafenamide hemifumarate | Aug, 2032 |
| Stribild | US9891239B2 | Modulators of pharmacokinetic properties… | Sep, 2029 |
Interested in knowing about Gilead Sciences Drug Patents Expiring in the next 10 years?
How Many Patents did Gilead Sciences File in Different Countries?
Countries in which Gilead Sciences Filed Patents
| Country | Patents |
| United States Of America | 2205 |
| Japan | 1114 |
| Australia | 1100 |
| Europe | 1085 |
| Hong Kong (S.A.R.) | 922 |
| Canada | 811 |
| China | 683 |
| Korea (South) | 593 |
| Germany | 509 |
| India | 470 |
| Israel | 469 |
| Taiwan | 464 |
| New Zealand | 433 |
| Spain | 420 |
| Singapore | 404 |
| Brazil | 384 |
| Mexico | 382 |
| Argentina | 298 |
| Portugal | 287 |
| Slovenia | 210 |
| Poland | 194 |
| Denmark | 188 |
| Austria | 159 |
| Viet Nam | 147 |
| South Africa | 142 |
| Indonesia | 136 |
| Chile | 130 |
| Peru | 115 |
| Cyprus | 108 |
| Croatia | 107 |
| Norway | 106 |
| Uruguay | 105 |
| Philippines | 102 |
| Macao | 93 |
| Costa Rica | 84 |
| Russian Federation | 80 |
| Malaysia | 79 |
| Hungary | 78 |
| Africa | 78 |
| Eurasian Patent Organization | 74 |
| Bolivia | 70 |
| United Kingdom | 63 |
| Colombia | 63 |
| Lithuania | 61 |
| Serbia | 58 |
| Ecuador | 48 |
| Turkey | 46 |
| Montenegro | 40 |
| Morocco | 37 |
| Dominican Republic | 30 |
| San Marino | 24 |
| Paraguay | 19 |
| Cuba | 16 |
| El Salvador | 16 |
| Czech Republic | 14 |
| Jordan | 14 |
| Netherlands | 12 |
| Brunei | 12 |
| Luxembourg | 12 |
| Ukraine | 12 |
| Iceland | 10 |
| Georgia | 8 |
| Saudi Arabia | 7 |
| Republic of Moldova | 6 |
| Gulf Cooperation Council | 5 |
| Guatemala | 4 |
| Belgium | 3 |
| Estonia | 2 |
| Panama | 2 |
| Ireland | 2 |
| Bulgaria | 2 |
| Belarus | 2 |
| Slovakia | 2 |
| Greece | 1 |
| Finland | 1 |
| Switzerland | 1 |
| United Arab Emirates | 1 |
| Mongolia | 1 |
| Nicaragua | 1 |
| Tunisia | 1 |
Where are Research Centers of Gilead Sciences Patents Located?
10 Best Gilead Sciences Patents
US6306393B1 is the most popular patent in the Gilead Sciences portfolio. It has received 961 citations so far from companies like Biogen, Genentech and UCB Biopharma.
Below is the list of 10 most cited patents of Gilead Sciences:
| Publication Number | Citation Count |
| US6306393B1 | 961 |
| US6187287B1 | 636 |
| US6653104B2 | 564 |
| US6183744B1 | 533 |
| US6331175B1 | 444 |
| US20050100543A1 | 428 |
| WO2010130034A1 | 406 |
| WO2002060492A1 | 396 |
| US7109304B2 | 387 |
| US7151164B2 | 376 |
Which Companies are using Gilead Sciences Patents to Advance their Research?
If patents or patents from a particular technology area of a company receive a lot of citations, it implies that the technology is being followed and incrementally innovated by the citing companies. It also indicates that citing companies are working on similar and closely related technologies.
The top citing companies in the Gilead Sciences patent portfolio are Roche Holding Ag, Abbvie and Idenix Pharmaceuticals Inc.
List of the top forward citing Companies –
| Company | Number of Patents |
| Roche Holding Ag | 17 |
| Abbvie Inc | 14 |
| Idenix Pharmaceuticals Inc | 14 |
| Merck Sharp & Dohme Corp | 9 |
| Ge Healthcare | 8 |
| Genentech | 8 |
| Bristol-Myers Squibb | 7 |
| Novartis | 7 |
| Enanta Pharmaceuticals | 6 |
| Viiv Healthcare Company | 6 |
Count of 102 and 103 Type Rejections based on Gilead Sciences Patents
Top Gilead Sciences Patents used in Rejecting Most Patent Applications
| Patent Number | Count of Rejected Applications |
| US9682143B2 | 14 |
| US9087043B2 | 13 |
| US8088368B2 | 11 |
| US7964580B2 | 9 |
| US20020041847A1 | 9 |
| US20040043030A1 | 8 |
| US7452524B2 | 8 |
| US7151164B2 | 8 |
| US7429572B2 | 8 |
| US7999083B2 | 7 |
| US7521056B2 | 7 |
| US7011816B2 | 7 |
| US7534866B2 | 7 |
| US8173621B2 | 6 |
| US7943118B2 | 6 |
What Percentage of Gilead Sciences US Patent Applications were Granted?
Gilead Sciences (Excluding its subsidiaries) has filed 1708 patent applications at USPTO so far (Excluding Design and PCT applications). Out of these 989 have been granted leading to a grant rate of 67.32%.
Below are the key stats of Gilead Sciences patent prosecution at the USPTO.
Which Law Firms Filed Most US Patents for Gilead Sciences?
| Law Firm | Total Applications | Success Rate |
| Gilead Sciences | 722 | 57.14% |
| Adsero Ip | 207 | 76.14% |
| Fish & Richardson | 99 | 68.67% |
| Mintz Levin Sfo | 42 | 89.66% |
| Ionis Pharmaceuticals | 37 | 100.00% |
| Cv Therapeutics | 33 | 38.46% |
| Max D Hensley | 30 | 75.00% |
| Viksnins Harris Padys Malen | 30 | 32.14% |
| Cooley Llp Gilead | 23 | 50.00% |
| Mark L Bosse | 23 | 53.85% |
EXCLUSIVE INSIGHTS COMING SOON!
What are Gilead Sciences‘ key innovation segments?
What Technologies are Covered by Gilead Sciences?
The chart below distributes patents filed by Gilead Sciences in different countries on the basis of the technology protected in patents. It also represents the markets where Gilead Sciences thinks it’s important to protect particular technology inventions.
R&D Focus: How Gilead Sciences search focus changed over the years?
EXCLUSIVE INSIGHTS COMING SOON!
Interested in knowing about the areas of innovation that are being protected by Gilead Sciences?
